Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials Review uri icon


MeSH Major

  • Antihypertensive Agents
  • Clinical Trials as Topic
  • Hypertension
  • Hypertrophy, Left Ventricular


  • A strict definition of the information required to establish a fully adequate surrogate end-point for morbid events in antihypertensive has been partially but not completely satisfied. The consistent relationship between baseline LVH and subsequent morbid events and the initial evidence of a parallelism between LVH change and prognosis need to be supplemented by additional studies that examine the latter relationship in diverse populations under varied treatments, and which examine the quantitative relationship between measured change in LVH and the subsequent rates of morbid events. Additional data will come from ongoing treatment trials (approximately 12 000 subjects) and observational studies (approximately 8000 subjects) with serial assessments of LVH.

publication date

  • November 28, 1996



  • Review



  • eng

PubMed ID

  • 8934385

Additional Document Info

start page

  • S95

end page

  • 101; discussion S101-2


  • 14


  • 2